Introduction/background: The Argus ® II is the first retinal prosthesis
Introduction
The dream of using electronic or artificial retinal replacements to treat blindness has long been held. With the advances in biotechnology, material science and understanding of visual and retinal neuroscience, this has finally become a reality for the first cohort of patients with outer retinal degeneration.
In the development of prosthetic vision, it is also possible to stimulate the visual pathway at other sites other than the retina to gain visual perceptions. These alternative approaches may be necessary in cases whereby the entire retina has been destroyed due to the disease nature, and include stimulation of the optic nerve head, [1] [2] [3] the lateral geniculate nucleus 4 and the primary visual cortex. 5, 6 The visual pathway functions as a complex image processor as well as an information conduit. At higher levels, the visual signals arrive with significant processing completed.
In reality due to its easier access, simpler processing and the retinotopic organization, the retina has been the primary focus for artificial stimulation. To date, visual prosthetic systems stimulating non-retinal sites are largely experimental and involve laboratory testing in animals and very limited numbers of human volunteers (see Table 1 ). Retinitis pigmentosa (RP) denotes a group of hereditary outer retinal degenerative diseases, affecting 1 in 4000 live births and 17 000 people worldwide. 7 Affected individuals suffer from progressive visual loss which can be profound (0.5% with no light perception, 25% with ≤20/200 vision in both eyes). 8 Treatment options for RP, other than for the associated cataract and macular oedema, have been limited. While recent advances in gene therapy, neuroprotective agents and stem cell therapy have shown promising future therapeutic potentials, [9] [10] [11] [12] retinal prostheses offer the only treatment option for patients at the severe end of the disease spectrum at present. There are currently two models of retinal prostheses available commercially: (i) Argus ® II retinal prosthesis system (Second Sight Medical Product, Inc., Sylmar), which received CE (Conformité Européenne) marking in March 2011 and the Food and Drug Administration (FDA) approval in February 2013 and (ii) the alpha-IMS (Retinal Implant AG, Reutlingen), which obtained CE marking in July 2013. In addition, the Argus ® II system is also presently under review by the Specialist Commissioning Group in the UK for the treatment of patients with end-stage RP in the National Health Service (NHS). Apart from technological advances in prosthetic vision, development in other biomedical fields has also shed new hope on restoring vision in patients with end-stage retinal diseases, most notably the cellular therapy. Current stem cell strategies include replacing the damaged retinal pigment epithelial (RPE) cells with embryonic stem cell (ESC)-derived RPE cells to rescue and partially restore photoreceptor function in retinal degenerative diseases. 13, 14 More recently studies replacing photoreceptors directly by subretinal insertion of committed precursors of photoreceptors from ESC have been reported. 15 Additionally, when the photoreceptors are still present, retinal gene therapy may be the key to preserve photoreceptor function and prevent cell death. 16 In this review, we will focus our discussion on the current status of various retinal prosthetic systems under development. In particular, the Argus ® II and alpha-IMS systems will be discussed in detail as they have been in extended clinical use.
Mechanism of the retinal prosthetic system
In RP and outer retinal dystrophies, the predominant pathology is the irreversible degeneration of the outer retina (i.e. the photoreceptors and the underlying RPE), while the remaining inner retina (i.e. bipolar cells, retinal ganglion cells) and the visual pathway downstream remain intact. 17 The success of a retinal prosthesis system, therefore, rests on reproducing the outer retinal function. This requires (a) efficient capturing of the visual images from the outside world; (b) transduction of the captured images into meaningful neurological signals; (c) subsequent activation of the residual inner retina (ganglion cells), from where visual information can be relayed to the visual cortex by the optic nerve. The second method takes a more naturalistic approach to image capture by making use of the subject's own optical system (the cornea and lens) to focus the visual images directly onto a photodiode, e.g. the alpha-IMS implant. 19 
Image translation
The external image-capturing system When an external video camera is employed for image capture, substantial amount of image processing takes place externally. The visuo-spatial information from the video is converted and encoded into electrical field patterns, which can then be used to activate the electrodes to stimulate the residual inner retina. In the Argus ® II retinal implant, this is achieved by real-time processing of the video images in a small portable computer unit known as the visual processing unit (VPU) (see Fig. 1a ). Examples of other groups which also use an external imaging system are the two German Consortiums: Intelligent Medical Implant (IMI) and EpiRet GmbH, whose devices are the IRIS implant and the Epi-Ret 3 implant, respectively. 20, 21 One advantage of an external system is that as image processing occurs extrinsic to the implanted subject, it allows for improvement of the visuospatial signal encoding. One of the main features of the IRIS-IMI device is the superior rendering of image processing by their 'learning algorithms', leading to the name Intelligent Medical Implant (see later section on IRIS-IMI). More recently, Nirenberg and Pandarinath 22 reported breakthrough in the encoding and translation of video images into recognizable visual forms, as observed in the changes in visual behaviour of experimental mice. This encoding is being developed in collaboration with the programmers of the Argus ® II retinal implants to allow incorporation into the next generation of retinal prosthetic systems.
The intrinsic image-capturing system
To make use of the subjects' own optical system for image capture, a photovoltaic component is placed in the posterior pole of the fundus, where it receives A), while the inner retina neurones require a threshold of ∼10 mA (10 −6 A) for activation.
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The alpha-IMS implant circumvented this problem by supplying an external power source, which amplifies the small currents generated by the MPDA sufficiently to activate the inner retina, while retaining the retinotopic organization of the stimuli. 19 In this system of intrinsic image capture, direct activation of the residual inner retina takes place instantaneously in a retinotopic manner. Image processing can potentially begin within the residual intra-retinal neural network.
Inner retina activation
Microelectronic stimulation (by microelectrode arrays) Stimulation of nerve endings with microelectrodes to activate voltage-gated ion channels in neurones is the basic mechanism of retinal activation for all current retinal prostheses. In a normal human retina, signals in bipolar cells and horizontal cells are represented in the form of graded intracellular electrical responses.
In the retinal ganglion cells, these local electrical responses are turned into action potentials and propagated down the optic nerve. Only retinal ganglion cells and amacrine cells are capable of producing action potentials.
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The microelectrode arrays have been placed at 3 different sites: Decisions on the choice of implant location also take into account factors such as implant biocompatibility, stability of the implant/retinal tissue interface, safety in terms of electrode charge density during active stimulation and the ease of surgical implantation or removal if required.
Aside from implant location, the other issue of greater interest is the level of visual resolution that retinal prostheses can deliver. In human retina there are ∼120 million rods, 6 million cones and 1.5 million ganglion cells. There is marked convergence in the retinal periphery where hundreds of rods feed into one peripheral bipolar cell, while in the central macular region (fovea), the ratio of cones to retinal ganglion cells approaches 1:1. Achieving this 1:1 ratio is unlikely with a retinal device because as the individual microelectrode diameter becomes smaller, the charge density (per unit area) increases exponentially 32 for the same supra-threshold stimulating current, thereby increasing the risk of tissue damage. 33 The microelectrodes array is also limited in its function by its size, as while larger overall stimulating area might offer a greater potential visual field for the patients, it would result in greater overall charge, which again may cause tissue damage. Even though the transfected neurones become light sensitive, they require constant luminance of 100 mW/cm 2 for action potential initiation. Natural ambient light (which has a variation of 15 log units in intensity) 26 does not have the intensity to activate the retina reliably. Wang et al. 36 from Stanford University devised an optoelectronic system, which combines the subretinal silicon MPDA similar to that of the ASR (Optobiotics) or the alpha-IMS system, with the targeted stimulation of the MPDA by pulsed near infra-red (NIR) lights to achieve inner retina activation. This has the potential of overcoming the limitation of microelectrode size and charge density with microelectrodes. It also offers the flexibility to process visual images with advanced encoding algorithms, before converting images into NIR pulses for subsequent MPDA stimulation. The third method of inner retinal stimulation, still at experimental stage, is the use of ultrasound waves to stimulate the retinal ganglion cells. Naor et al. (a) a glasses mounted video camera; (b) a portable computer (the VPU) for processing the captured images; (c) an external coil, built into the side arm of the glasses, for wireless communication using radiofrequency (RF) telemetry and induction of power.
Retinal prostheses in clinical practice
The internal part consists of (a) an internal coil which receives RF telemetry from the external coil and converts the RF back into electric signals;
(b) an application-specific-internal-circuit (ASIC), receives data and power in the form of electric signals from the internal coil and generates appropriate electrical pulses for microelectrode stimulation; (c) a 60-microelectrode epiretinal array covering a 20°field of vision, held in place by a retinal tack (see Fig. 1b ).
The internal coil and ASCI are sealed in a protective hermetic casing, which is placed on the surface of the globe, while the 60-microelectrode array is the only portion of the device that is placed intra-ocularly. These two portions are connected via a cable that traverses the sclera. Surgically, the Argus ® II device can be implanted using common vitreoretinal surgical techniques with a surgical time of ∼2-3 h. It has also been shown that the device can be safely removed without any serious adverse effect. 18 Data from the 30 patients implanted during the phase II clinical trial showed a good safety profile, including the demonstration that the Argus ® II is safe for magnetic resonance imaging (MRI) up to the strength of 3-T in its switched-off state (without the external parts). 38 Three Argus ® II patients have since undergone MRI brain scans for unrelated medical conditions, with no detrimental effects to the patients or to the device function. 39 Conjunctival erosion is the commonest complication experienced by the patients (10%) with all except one being treated satisfactorily by re-suturing. During the trial, one patient's device had to be explanted due to recurrent erosions and one patient developed retinal detachment which was successfully repaired. Two patients developed endophthalmitis but all were treated successfully with intra-vitreal antibiotics and the patients retained good functional use of their device. All the three patients were implanted early on in the trial and with amendment to the implantation protocol, none of the subsequent patients developed endophthalmitis. 18 Twenty-eight patients underwent functional assessments and all reported reliable perception of phosphenes. Orientation and mobility functions were tested by following a white line on a dark floor, and locating a dark door on a white wall from the centre of a room. Patients performed significantly better with the device switched on compared with the device switched off. 18 More than half of these patients (15/28) were also able to identify the direction of motion, as tested by showing them a high-contrast bar moving in varying directions on a flat LCD screen. 40 In assessing visual discriminatory function, some of the patients were able to localize squares 41 or even discriminate different geometric shapes 42 when presented with high-contrast targets on a flat LCD screen, using the Argus ® II device. More recently, da
Cruz et al. published outcomes from 21 eligible subjects showing more accurate discrimination of large letters with device on compared with their native vision (P < 0.001). Four subjects were able to consistently read unrehearsed short words of up to four letters. 43 The best grating visual acuity is logMAR 1.8 (Snellen equivalent of 20/1262) from worse than logMAR 2.9 pre-op. 18 
Alpha-IMS: Retinal Implant AG, Reutlingen, Germany
The first generation of Retinal Implant AG devices were originally implanted in 11 subjects in 2005 as part of an acute clinical trial (Clinical Trials.gov NCT00515814). 44 It consisted of a 16 electrode array for direct electrical stimulation of the retina, as well as the light-sensitive photovoltaic MPDA. The implant was placed subretinally and powered externally by a percutaneous wire, which exited in the retro-auricular region of the subject as a connection plug. Although visual function improvement was demonstrated, the implant was removed from all the subjects after a few weeks as per protocol (except in one subject who declined removal) and no long-term durability data are available from the acute trial.
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A second-generation device, the alpha-IMS, which features some design improvement, showed good safety profile with promising visual outcomes including the first demonstration of letter and word recognition in an implanted subject. 19, 46 A multi-centre phase II clinical trial with alpha-IMS has begun (www.clinicaltrials.gov, NCT01024803), with the ophthalmology department of the John Radcliffe Hospital at Oxford and King's College Hospital in London being amongst the trial centres. The alpha-IMS received its CE marking in July 2013.
The alpha-IMS, unlike the Argus ® II, utilizes the subject's own eye to capture the images and hence does not have an external video camera. Structurally, the alpha-IMS is also made up of an internal part and an external part. The internal part (see Fig. 3a and b) consists of (a) a subretinal photovoltaic silicon MPDA; (b) an internal induction coil which is buried subdermally in the retro-auricular region; (c) a silicone cable connecting the MPDA to the internal coil.
Within each MPDA, there are 1500 photosensitive pixel-generating elements; each photodiode is further connected to an independent titanium nitride microelectrode via an amplifier. The MPDA is designed to be inserted subretinally to allow reception of the visual images focused on to the retina by the front of the eye. Image conversion is achieved by light intensity-dependent generation of photocurrent by each photodiode, which is then amplified logarithmically before feeding into the associated microelectrode to stimulate the immediate retinal neurones. 19 Ideally, the 3 mm × 3 mm microchip implant should be placed sub-foveally or as close to the fovea as possible to allow optimal stimulation of the MPDA by the incoming light, resulting in a visual field of 11°× 11°. The silicone cable connecting the MPDA leaves the eye trans-choroidally to reach the lateral orbital rim, before tunnelling underneath the temporalis muscle in the sub-periosteal space to reach the retro-auricular region where it terminates in the internal coil (see Figure 3b ). Electrical energy is generated by internal coil induction with an external coil, and subsequently used to amplify the MPDAelectrode system response. 47 Due to the extensive extraocular path of the connecting silicone cable, surgical implantation of the alpha-IMS device requires a multi-disciplinary surgical team involving vitreoretinal, oculoplastics and ENT/maxillofacial surgeons. The entire procedure typically takes ∼6-7 h and surgical removal is possible without serious complications.
Preliminary results on the performance of the first generation implant have been reported on three patients. 19 All the three subjects are able to respond to flash light reliably, discern orientations of moving gratings and recognize some objects such as cups or saucers on the table. One subject in particular was able to recognize geometric shapes and read large letters to formulate simple words. A possible explanation for his superior visual performance is that his MPDA is implanted sub-foveally, whereas the other two subjects' are located extrafoveally. Stingl et al. 46 have since published a report on the first 10 patients implanted with the secondgeneration device, followed up for 3-9 months. Two adverse events were reported: one patient developed post-operative subretinal bleed with secondary intra-ocular pressure rise to 46 mmHg, which settled on medical treatment. The other patient suffered intra-operative optic nerve damage when the tip of the implant touched the optic nerve, resulting in no perception of light (NPL) vision post-operatively. Despite the adverse events, the visual outcomes have been favourable: three patients were able to recognize individual letters spontaneously when presented under high contrast conditions, with the best visual acuity reported to be logMAR 1.43 (Snellen visual acuity 20/546). The Epi-Ret 3 is the third generation device by Epi-Ret GmH. The main difference between Epi-Ret 3 and other video glasses devices is that the internal coil and ASIC hermetic case are packaged into a compact disc form similar in dimension to that of an intra-ocular lens and inserted into the capsular bag. 50 The acute trial of EPI-RET 3 was carried out in 2007 in which six patients were implanted with the device for 4 weeks. All the patients reported phosphene phenomena such as dots, arcs or lines.
German consortiums: IRIS-IMI GmBH and Epi-Ret 3-Epi-Ret GmBH
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Other retinal prosthetic systems
Other groups that have been involved in the development of prosthetic vision include the Optobionic Corporation (by Dr Alan Chow) who developed the artificial silicon retina. 52 These silicon wafer discs were 2 mm in diameter and 25 μm thick, containing 5000 photodiodes each, and were designed for subretinal implantation. Unfortunately, the silicon photodiodes alone were unable to generate adequate electric currents to activate the overlying bipolar cells. 24 The Boston Retinal Implant Project (established in 1980s) initially worked on an epiretinal system using an external video camera for image capture, external computer image processing and direct stimulation of the retina with epiretinally implanted microelectrode array. The group's early pioneering work on establishing safety threshold for micro-stimulation and on biocompatibility and hermetic sealing of the implant materials have been invaluable for the development of future generations of retinal prostheses. 53, 54 Ongoing retinal prosthesis projects Developments of both devices are still in their infancy with their first prototype containing 24 electrodes being implanted in September 2012.
Areas of controversy
Current retinal prostheses can be grossly divided into those that use an external apparatus for image capture (e.g. Argus ® II) versus those that utilize the patient's own optical focusing system (e.g. alpha-IMS). One of the main criticisms of using an external imaging system is that image capturing occurs independently of eye position. Normal localization of an object in visual space is dependent on the retinotopic position of the target relative to the position of the subject's eye and head. As such hand eye co-ordination could theoretically be limited. Although this may initially be an issue, there is evidence that Argus ® II subjects showed functional improvement in orientation and mobility, 18 as well as their ability to localize squares by pointing on the LCD flat screen, with the use of the device. 41 Conversely, the use of an external image capture and processing system may bypass the loss of intra-retinal processing due to intra-retinal neural remodelling in these patients with end-stage RP. 57 Neural remodelling could pose a potentially serious problem for the intrinsic image-capturing system, as it relies on the integrity of the residual intrinsic retinal network for image processing.
A great challenge with the artificial vision offered by the retinal prostheses is the problem of image persistence. At present, even though the Argus ® II retinal prosthesis reliably produces phosphenes in response to visual stimuli, the perceived image may fade quickly in a matter of seconds. For a subject to continuingly 'see' an object, he/she may need to 'refresh' the images captured by the video camera by shaking his/her head, so as to reproduce the phosphenes. As human eyes naturally undergo constant micro-saccades even when fixating on an object, these micro-movements may provide a means of constantly refreshing the visual stimuli to provide constant phosphene perception in an intrinsic imagecapturing system (e.g. alpha-IMS). However, it is interesting to note that two of the Argus ® II patients perceive constant images without having to consciously shake their heads. 58 It is possible that these two patients have retained greater number of the W-or X-type of retinal ganglion cells, which have been shown to give sustained responses to light stimuli. A final area of contention is over the optimal placement of the prostheses, i.e. subretinal versus epiretinal. The advantage of subretinal implants may be the direct stimulation of bipolar cells as photoreceptors naturally do. This may allow natural image processing within the retina prior to ganglion cell activation. However, as previously discussed, current generation of subretinal electrodes are in the order of tens of micrometres (μm) in diameter and would not stimulate individual bipolar cells. Furthermore, Chen et al. 59 suggested that the electrical field from the microelectrode stimulation spreads through the entire retina, stimulating both bipolar and ganglion cells, rendering the position of the stimulating array irrelevant, whether epiretinal or subretinal.
Areas for future developments
Over the past two decades, the development of retinal prostheses has come a long way to achieve the bio-stability and safety that is required for the integration of an electronic system into humans. The next goal would be to improve the quality of vision. To achieve this, improvement on all the following three aspects are necessary:
(a) Improve the visual acuity by achieving specific, focal activation of retinal ganglion cells. (b) Improve the visual field by increasing the area of retina we can activate safely without tissue damage. (c) Improve our understanding of intra-retinal visual processing circuitry so that we could eventually formulate an accurate encoding system to convert the high quality of images we capture with video cameras today into neurologically meaningful signals for our visual cortex interpretation.
Conclusion
After decades of research, the dream of producing a bionic eye to provide artificial vision for blind patients has finally been realized. Two separate
